Michael Davidson to Azetidines
This is a "connection" page, showing publications Michael Davidson has written about Azetidines.
Connection Strength
4.330
-
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013 Nov; 10(11):618-9.
Score: 0.402
-
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013 Oct; 230(2):322-9.
Score: 0.400
-
Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
Score: 0.295
-
Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
Score: 0.280
-
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
Score: 0.280
-
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
Score: 0.244
-
Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):455-62.
Score: 0.234
-
Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006 Jan 15; 97(2):223-8.
Score: 0.234
-
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
Score: 0.220
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.214
-
Newer pharmaceutical agents to treat lipid disorders. Curr Cardiol Rep. 2003 Nov; 5(6):463-9.
Score: 0.203
-
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
Score: 0.199
-
Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
Score: 0.196
-
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
Score: 0.191
-
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
Score: 0.100
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.089
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
Score: 0.086
-
Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
Score: 0.084
-
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
Score: 0.073
-
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
Score: 0.062
-
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
Score: 0.061
-
Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
Score: 0.053
-
Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
Score: 0.047
-
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
Score: 0.042
-
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012 Oct; 51(4):314-24.
Score: 0.023
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.019